540 related articles for article (PubMed ID: 28161506)
1. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
3. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
5. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma.
Liang Y; Chen J; Yu Q; Ji T; Zhang B; Xu J; Dai Y; Xie Y; Lin H; Liang X; Cai X
Cancer Med; 2017 Dec; 6(12):2787-2795. PubMed ID: 29030911
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
Chen JC; Chuang HY; Hsu FT; Chen YC; Chien YC; Hwang JJ
Oncotarget; 2016 Dec; 7(51):85450-85463. PubMed ID: 27863427
[TBL] [Abstract][Full Text] [Related]
8. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
9. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
10. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A
Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071
[TBL] [Abstract][Full Text] [Related]
11. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
[TBL] [Abstract][Full Text] [Related]
12. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683
[TBL] [Abstract][Full Text] [Related]
14. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
[TBL] [Abstract][Full Text] [Related]
15. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
Chen Y; Liu YC; Sung YC; Ramjiawan RR; Lin TT; Chang CC; Jeng KS; Chang CF; Liu CH; Gao DY; Hsu FF; Duyverman AM; Kitahara S; Huang P; Dima S; Popescu I; Flaherty KT; Zhu AX; Bardeesy N; Jain RK; Benes CH; Duda DG
Sci Rep; 2017 Mar; 7():44123. PubMed ID: 28276530
[TBL] [Abstract][Full Text] [Related]
16. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
[TBL] [Abstract][Full Text] [Related]
17. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
Wei G; Wang M; Hyslop T; Wang Z; Carr BI
Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
[TBL] [Abstract][Full Text] [Related]
18. AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Toh HC; Thng CH; Chow P; Ong HS; Chung A; Goh BC; Smith PD; Soo KC
J Hepatol; 2010 Jan; 52(1):79-87. PubMed ID: 19910069
[TBL] [Abstract][Full Text] [Related]
19. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
[TBL] [Abstract][Full Text] [Related]
20. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
Gedaly R; Galuppo R; Musgrave Y; Angulo P; Hundley J; Shah M; Daily MF; Chen C; Cohen DA; Spear BT; Evers BM
J Surg Res; 2013 Nov; 185(1):225-30. PubMed ID: 23769634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]